Loading...
XSHE300482
Market cap1.43bUSD
Jan 15, Last price  
21.96CNY
1D
-0.81%
1Q
-9.52%
Jan 2017
-30.78%
IPO
305.58%
Name

Guangzhou Wondfo Biotech Co Ltd

Chart & Performance

D1W1MN
XSHE:300482 chart
P/E
21.53
P/S
3.80
EPS
1.02
Div Yield, %
2.17%
Shrs. gr., 5y
0.39%
Rev. gr., 5y
10.88%
Revenues
2.76b
-51.33%
183,422,000227,353,601247,643,090365,395,892428,779,834547,353,2861,145,484,4831,650,059,4302,072,320,9012,810,841,2543,361,043,2775,680,513,1742,764,914,157
Net income
488m
-59.26%
31,672,40037,908,54959,003,54898,364,048125,351,543144,986,730210,695,013307,744,491387,461,316634,170,281634,433,1451,197,063,465487,624,779
CFO
388m
-76.92%
23,834,30074,836,212100,913,873104,470,301131,814,344112,007,117168,850,527247,609,248309,860,0701,061,837,071664,930,2901,682,171,310388,192,882
Dividend
Jun 05, 20240.4 CNY/sh
Earnings
May 16, 2025

Profile

Guangzhou Wondfo Biotech Co.,Ltd, a biological company, engages in the research and development, production, and sale of point-of-care testing products, and rapid diagnosis and chronic disease management solutions. The company offers rapid test kits for COVID-19, drug of abuse, tumor, infectious, fertility, and sexually transmitted diseases, as well as immunofluorescence devices to detect cardiovascular diseases, inflammation, kidney injury, sex hormones, thyroid function, diabetes, tumor, and other diseases. It also provides blood gas, optical coagulation, and dry chemistry analyzers. The company was founded in 1992 and is headquartered in Guangzhou, China.
URL
https://www.wondfo.com/index
IPO date
Jun 30, 2015
Employees
Domiciled in
CN
Incorporated in
CN

Valuation

Title
CNY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
2,764,914
-51.33%
5,680,513
69.01%
Cost of revenue
2,155,750
4,164,905
Unusual Expense (Income)
NOPBT
609,164
1,515,608
NOPBT Margin
22.03%
26.68%
Operating Taxes
53,334
174,501
Tax Rate
8.76%
11.51%
NOPAT
555,830
1,341,107
Net income
487,625
-59.26%
1,197,063
88.68%
Dividends
(227,953)
(132,787)
Dividend yield
1.70%
0.94%
Proceeds from repurchase of equity
(30,100)
(1)
BB yield
0.22%
0.00%
Debt
Debt current
221,222
Long-term debt
608,220
554,863
Deferred revenue
37,212
23,095
Other long-term liabilities
1
1
Net debt
(1,663,999)
(1,670,649)
Cash flow
Cash from operating activities
388,193
1,682,171
CAPEX
(432,734)
Cash from investing activities
(113,395)
Cash from financing activities
(542,023)
35,332
FCF
(501,244)
1,010,858
Balance
Cash
1,562,743
2,100,585
Long term investments
709,475
346,149
Excess cash
2,133,973
2,162,708
Stockholders' equity
3,981,571
3,802,214
Invested Capital
3,098,393
3,076,341
ROIC
18.00%
50.20%
ROCE
11.52%
28.62%
EV
Common stock shares outstanding
443,295
441,686
Price
30.19
-5.27%
31.87
-19.07%
Market cap
13,383,084
-4.93%
14,076,525
-19.43%
EV
12,078,803
12,599,678
EBITDA
886,276
1,785,918
EV/EBITDA
13.63
7.06
Interest
32,200
31,065
Interest/NOPBT
5.29%
2.05%